Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ELVN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 463.42M
March 31, 2026 10.05M
December 31, 2025 0.623M
September 30, 2025 -0.368M
June 30, 2025 218.38M
March 31, 2025 0.234M
December 31, 2024 39.97M
September 30, 2024 1.117M
June 30, 2024 1.806M
March 31, 2024 90.27M
December 31, 2023 0.09M
September 30, 2023 -0.425M
June 30, 2023 -2.82M
March 31, 2023 237.44M
Date Value
December 31, 2022 -1.811M
September 30, 2022 0.164M
June 30, 2022 0.005M
March 31, 2022 0.409M
December 31, 2021 -0.01M
September 30, 2021 46.99M
June 30, 2021 1.66M
March 31, 2021 0.46M
December 31, 2020 0.597M
September 30, 2020 0.135M
June 30, 2020 9.593M
March 31, 2020 86.56M
December 31, 2019 -1.996M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Definium Therapeutics, Inc. 758.70M
Cocrystal Pharma, Inc. 0.00
CNBX Pharmaceuticals, Inc. 0.045M
GB Sciences, Inc. --
Arvinas, Inc. 0.40M